Skip to main content
. 2025 Aug 12;16:1602047. doi: 10.3389/fimmu.2025.1602047

Figure 2.

Violin plots compare IVIg and PAIA treatments over time. Panel A depicts mRS scores, with decreasing values over 90 days. Panel B shows CASE scores, also decreasing over time. Significant differences are indicated by asterisks.

Clinical efficacy of IVIg and PAIA. (A) Significant decreases in mRS scores were observed at 30 days and 90 days after IVIg treatment (30 days, Z = -3.494, p < 0.001; 90 days, Z = -4.562, p < 0.001) and PAIA treatment (30 days, Z = -3.852, p < 0.001; 90 days, Z = -4.178, p < 0.001). (B) Significant decreases in CASE scores were also observed at 30 days and 90 days after IVIg treatment (30 days, t = 7.762, p < 0.001; 90 days, t = 11.949, p < 0.001) and PAIA treatment (30 days, t = 8.782, p < 0.001; 90 days, Z = -4.079, p < 0.001). mRS, modified Rankin scale; CASE, Clinical Assessment Scale for Autoimmune Encephalitis; IVIg, intravenous immunoglobulin; PAIA, protein A immunoadsorption. *P<0.025.